Scientific Sessions


The sessions below reflect the invited program only. Visit the Virtual Program to view the complete schedule — including all plenary sessions, live sessions, on-demand sessions and poster presentations — each guided by a daily research theme.

All times are listed in Central Daylight Time (North America).

On This Page:

Plenary Sessions


10-10:30 a.m. CDT

The Two Indias

Viji Ravindranath, Ph.D.
Indian Institute of Science, India
Theme: Basic Science and Pathogenesis

10:30-11 a.m. CDT

Inge Grundke-Iqbal Award for Alzheimer’s Research: Resistance to Autosomal Dominant Alzheimer's Disease

Yakeel Quiroz, Ph.D.
Massachusetts General Hospital, United States
Theme: Basic Science and Pathogenesis

10:30-11 a.m. CDT

Proteostasis Failure in Alzheimer’s Disease and Related Dementias — New Clues to Pathogenesis and Therapy

Ralph A. Nixon, M.D., Ph.D.
Nathan S. Kline Institute for Psychiatric Research; NYU Langone Medical Center, United States
Theme: Basic Science and Pathogenesis

10-10:30 a.m. CDT

Imaging Biomarkers and Alzheimer's Prevention

Susan M. Landau, Ph.D.
Helen Wills Neuroscience Institute, University of California, Berkeley, United States
Theme: Biomarkers

10:30-11 a.m. CDT

Blood Based Biomarkers

Charlotte Teunissen, Ph.D.
Amsterdam UMC, Netherlands
Theme: Biomarkers

10-10:30 a.m. CDT

Mechanisms of Neurovascular Dysfunction and Interaction with Alzheimer's Disease Pathology

Costantino Iadecola, M.D.
Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, United States
Theme: Clinical Manifestations

10:30-11 a.m. CDT

Early-Onset Alzheimer's Disease

Nick Fox, M.D.
University College London, United Kingdom
Theme: Clinical Manifestations

10-10:30 a.m. CDT

Global Guidelines for Dementia Risk Reduction

Kaarin Anstey, Ph.D.
UNSW Ageing Futures Institute; NeuRA; ARC Centre of Excellence in Population Ageing Research; NHMRC Dementia Centre for Research Collaboration, Australia
Theme: Dementia Care and Psychosocial Factors and Public Health

10:30-11 a.m. CDT

Epidemiology of Dementia and Cognitive Decline in Diverse Populations

Lisa L. Barnes, Ph.D.
Rush Alzheimer’s Disease Center, United States
Theme: Dementia Care and Psychosocial Factors and Public Health

Symposium Sessions

Dementia and Cognitive Health in LGBTQ Older Adults

Session Chairs: Maria M. Corrada, Ozioma Okonkwo

  • Interventions for LGBTQ Older Adults With ADRD and Their Care Partners
    Karen Fredriksen-Goldsens, University of Washington, United States
  • The Epidemiology of ADRD in LGBTQ Older Adults
    Jason Flatt, University of Nevada, Las Vegas; University of California, San Francisco, San Francisco, United States
  • LGBTQ Older Adults With Cognitive Impairment: Implications for Early Diagnosis, Treatment and Care
    Sue Westwood, University of York, United Kingdom
  • Sociolegal and Practice Implications of Caring for LGBTQ People With Dementia
    Rosie Harding, Birmingham Law School, United Kingdom

Ethics in Dementia

Session Chairs: Frank Jessen, Carey Gleason

  • Ethical and Practical Challenges in Disclosure of APOE Genotype
    J. Scott Roberts, University of Michigan, United States
  • Expectations and Effects of Biomarker-Based Dementia Risk Prediction in MCI — The PreDaDQual Project
    Ayda Rostamzadeh, University of Cologne, Germany
  • Ethical Considerations on Individualized Risk Prediction in MCI — The ABIDE Project
    Jetske van der Schaar, Amsterdam UMC, Netherlands
  • Amyloid Disclosure in Mild Cognitive Impairment
    Jennifer Lingler, University of Pittsburgh, United States

Immunity in The Aging or Diseased Brain

Session Chairs: Sergio Ferreira, Jose F. Abisambra

  • The Bidirectional Communication Between the Brain and the Systemic Immune System in Aging
    Marina Lynch, Trinity College Institute of Neuroscience, Ireland
  • Trem2- Independent Activity of PD-L1 Immunotherapy in Modifying Alzheimer’s Disease in Mouse Models
    Michal Schwartz, Weizmann Institute of Science, Israel
  • Microglial Immune Memory and Metabolic Reprogramming Modifies Amyloid Structure and Neuronal Dystrophy in Mouse Models of Alzheimer’s Pathology
    Jonas Neher, German Center for Neurodegenerative Diseases (DZNE); Hertie Institute for Clinical Brain Research, Germany

Measuring Tau Accumulation and Progression

Session Chairs: Kejal Kantarci, Brad Dickerson

  • Tau Progression Evidence From Tau PET Imaging
    Rik Ossenkoppele, Alzheimer Center Amsterdam; Vrije Universiteit Amsterdam, Amsterdam UMC, Netherlands; Lund University, Sweden
  • Pathologic Progression of Tau
    Gabor Kovacs, University of Toronto, Canada
  • Multi-omic Approach to Tau Accumulation and Progression
    Philip De Jager, Columbia University Medical Center, United States
  • Interaction of Tau With Other Pathologies
    Virginia Lee, Perelman School of Medicine at the University of Pennsylvania, United States

Mechanisms of White Matter Damage

Session Chairs: Roxana Carare, Delphine Boche

  • Understanding the Pathophysiology of Amyloid-Related Imaging Abnormalities (ARIA) Following Aβ Immunotherapy
    James Nicoll, University of Southampton, United Kingdom
  • Biomarkers of Vascular Cognitive Impairment and Dementia; Informing Disease Mechanisms
    Donna Wilcock, University of Kentucky Sanders Brown Center on Aging, United States
  • Trauma-Related Axonal Damage
    Victoria Johnson, University Of Pennsylvania, United States
  • Neuroimaging of White Matter Hyperintensities (WMH)
    Joanna Wardlaw, University of Edinburgh, United Kingdom

Repurposing Drugs Targeting Glia and Inflammatory Mechanisms

Session Chairs: Linda Van Eldik, Cynthia Lemere

  • Targeting solTNF to Reduce Risk and Progression of Alzheimer’s Disease and Other Dementias
    Malú Tansey, University of Florida College of Medicine, United States
  • Repurposing Senotlytic Therapies for Alzheimer’s Disease
    Howard Fillit, Alzheimer’s Drug Discovery Foundation, United States
  • Microglial Cells in AD: Good Guys or Bad Guys?
    Knut Biber, AbbVie Deutschland GmbH & Co. KG, Germany
  • Finding New Uses for Old Drugs in Alzheimer’s Disease
    Clive Ballard, University of Exeter Medical School, United Kingdom

Towards a Precision Medicine Approach in Alzheimer’s Disease

Session Chairs: Jonathan Schott, Wiesje van Der Flier

  • Blood-Based Biomarkers to Predict Current and Future Alzheimer’s Disease
    Randall Bateman, Washington University in St. Louis School of Medicine, United States
  • Accurate Prediction of β-Amyloid Positivity Using Risk Models and Plasma Aβ and P-tau Analyses
    Sebastian Palmqvist, Lund University; Skåne University Hospital, Sweden
  • Biomarker-Based Prognosis for People With Mild Cognitive Impairment
    Ingrid van Maurik, Alzheimer Center Amsterda; Vrije Universiteit Amsterdam, Amsterdam UMC, Netherlands
  • Organizing Mechanistic Knowledge About Neurodegenerative Diseases for the Improvement of Drug Development and Therapy
    Martin Hofmann-Apitius, Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Sankt Augustin; Bonn-Aachen International Center for IT (b-it), Germany

Using Technology to Improve Access to Cognitive Assessments and Interventions

Session Chairs: Maureen Schmitter-Edgecombe, Rema Raman

  • Unsupervised Online Neuropsychological Testing — The Principles
    Paul Maruff, The Florey Institute of Neuroscience and Mental Health, Australia
  • Socially Assistive Robots for Cognitive and Social Stimulation
    Jesus Favela, CICESE Research Center, Mexico
  • Testing on Mobile Devices
    Simon Collinson, Savonix, Singapore

Join ISTAART and Attend AAIC Online at No Cost!

Not an ISTAART member? Select the ISTAART + AAIC Bundle during registration. You’ll receive year-long ISTAART membership and all its benefits, including global networking opportunities, exclusive webinars, career resources and much more — plus free AAIC registration.


Join the Conversation #AAIC21






> 1200px
> 992px
> 768px
< 767px